Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 0.73 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.50 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL142044 | 1.00 | CHRM3 (0.73) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL141731 | 0.85 | CHRM3 (1.00) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL141730 | 0.85 | CHRM3 (1.00) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL3911327 | 0.83 | CHRM3 (0.50) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL4166137 | 0.80 | CHRM3 (0.88) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL4166138 | 0.80 | CHRM3 (0.88) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL143848 | 0.75 | CHRM3 (0.83) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL143847 | 0.75 | CHRM3 (0.83) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL244458 | 0.74 | CHRM3 (0.40) | CHRM3CHRM1KMT2ALMNAADRA2B | |
| Bromide SCHEMBL5039534 | 0.73 | CHRM3 (0.74) | CHRM3CHRM1CHRM2APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178395-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | claimed |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| CN-110785420-B | Oxazepin derivatives as inhibitors of PI 3-kinase activity | 葛兰素史克知识产权开发有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3612536-B1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| EP-1756120-A1 | PURINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20070043007-A1 | Specific glucocorticosteroid compounds having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20060293298-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| US-20060247219-A1 | Specific glucocorticosteriod compound having anti-inflamatory activity | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060178395-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| WO-2006062883-A2 | MEDICAL COMBINATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | US | disclosed |
| WO-2005116037-A1 | PURINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793559-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | CHRM3 3771/4885CHRM1 4169/4885CHRM2 4440/4885 |
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CHRM3 4030/4885CHRM1 4207/4885CHRM2 4500/4885 |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | CHRM3 4065/4885CHRM1 4329/4885CHRM2 4667/4885 |
| US-20060293298-A1 | Compounds | NQO1, OPRM1, CAT | CHRM3 1901/4885CHRM1 1558/4885CHRM2 2314/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CHRM3 4030/4885CHRM1 4207/4885CHRM2 4500/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | CHRM3 3764/4885CHRM1 4447/4885CHRM2 4617/4885 |
| US-20060178395-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM1 19/4885CHRM2 3/4885 |
| US-20060247219-A1 | Specific glucocorticosteriod compound having anti-inflamatory activity | NR3C1, NR3C2, MC2R | CHRM3 225/4885CHRM1 135/4885CHRM2 280/4885 |
| US-20070043007-A1 | Specific glucocorticosteroid compounds having anti-inflammatory activity | NR3C2, NR3C1, NR5A1 | CHRM3 737/4885CHRM1 1415/4885CHRM2 1488/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | CHRM3 3446/4885CHRM1 4288/4885CHRM2 4347/4885 |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | HRH2, HRH4, HRH1 | CHRM3 734/4885CHRM1 1028/4885CHRM2 1361/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | CHRM3 1182/4885CHRM1 1223/4885CHRM2 1917/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | CHRM3 4226/4885CHRM1 4260/4885CHRM2 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.